Clinical Trial Update: Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating NP-120 for idiopathic pulmonary fibrosis shows results on efficacy, safety, and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• NP-120 (ifenprodil)

Snippet

Sponsor: Algernon Pharmaceuticals | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: COMPLETED